Clinical trials: Solid Tumor in Children
Solid Tumors, Lymphoma
Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma
Background: Imetelstat is a cancer treatment drug that may slow or stop tumor growth. It may also prevent tumors from spreading to other parts of the body.
- Trial name
- NCT01568632
- Testing
- Imetelstat
- Sponsor
- National Cancer Institute (NCI)
Central Nervous System Embryonal Tumor With Rhabdoid Features, Central Nervous System Embryonal Tumor, Not Otherwise Specified
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors
This phase I/II trial studies the side effects and best dose of adavosertib and irinotecan hydrochloride in treating younger patients with solid tumors that have come back (relapsed) or that have not responded to standard therapy…
- Conditions
- Central Nervous System Embryonal Tumor With Rhabdoid Features, Central Nervous System Embryonal Tumor, Not Otherwise Specified, Central Nervous System Ganglioneuroblastoma, Embryonal Tumor With Multilayered Rosettes, C19MC-Altered
- Trial name
- NCT02095132
- Testing
- Adavosertib, Irinotecan Hydrochloride
- Where
- 24 sites in United States, Canada
- Volunteers
- 76 people
- Sponsor
- National Cancer Institute (NCI)
Analgesic, Enhanced Recovery After Surgery
Acetaminophen Before Surgery Lowers Postop Pain in Pediatric Solid Tumor Patients (ERAS)
Pain is the predominant subjective symptom experienced during the perioperative period in pediatric patients with solid tumors. Intense pain may impede early postoperative activities and delay the recovery process.
- Conditions
- Analgesic, Enhanced Recovery After Surgery, Postoperative Pain, Acetaminophen
- Trial name
- NCT07095816
- Testing
- Acetaminophen, Sterilized water
- Where
- China
- Volunteers
- 182 people
- Sponsor
- Nanjing Children's Hospital
Melanoma, Lymphoma
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Researchers are looking for new ways to treat children with different types of melanoma (skin cancer), solid tumors, and lymphomas (blood cancers) that are any of these: Advanced, which means cancer spread in the body or cannot…
- Conditions
- Melanoma, Lymphoma, Solid Tumor, Classical Hodgkin Lymphoma
- Trial name
- NCT02332668
- Testing
- Pembrolizumab
- Where
- 16 sites in United States, Brazil and 8 more
- Volunteers
- 370 people
- Sponsor
- Merck Sharp & Dohme LLC
Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Malignant Solid Neoplasm
Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
This phase 1/2 trial the studies side effects and best dose of crizotinib and to see how well it works in treating young patients with solid tumors or anaplastic large cell lymphoma that has returned after a period of improvement…
- Conditions
- Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Refractory Anaplastic Large Cell Lymphoma
- Trial name
- NCT00939770
- Testing
- Crizotinib, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 28 sites in United States, Canada
- Volunteers
- 122 people
- Sponsor
- Children's Oncology Group
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Vincristine Pharmacokinetics in Infants
This pilot trial compares drug exposure levels using a new method for dosing vincristine in infants and young children compared to the standard dosing method based on body surface area (BSA) in older children.
- Trial name
- NCT05359237
- Testing
- Biospecimen Collection, Vincristine
- Where
- 29 sites in United States, Australia and 1 more
- Volunteers
- 83 people
- Sponsor
- Children's Oncology Group
Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia
Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate
This phase I trial is studying the side effects and best dose of dasatinib in treating young patients with recurrent or refractory solid tumors or Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Childhood Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Trial name
- NCT00316953
- Testing
- dasatinib, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Ewing's Sarcoma, Osteosarcoma
HGS-ETR2 to Treat Children With Solid Tumors
Background HGS-ETR2 is a monoclonal antibody, produced in the laboratory from human genes. HGS-ETR2 targets a protein called the TRAIL receptor that is located on the surface of some tumor cells.
- Conditions
- Ewing's Sarcoma, Osteosarcoma, Neuroblastoma, Rhabdomyosarcoma
- Trial name
- NCT00428272
- Testing
- Lexatumumab alone, Lexatumumab in combination, Interferon gamma 1b in combination
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Pediatric Solid Tumor, Germ Cell Tumor
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
This is a phase I, open-label, non-randomized study that will enroll pediatric and young adult research participants with relapsed or refractory non-CNS solid tumors to evaluate the safety, feasibility, and efficacy of…
- Conditions
- Pediatric Solid Tumor, Germ Cell Tumor, Retinoblastoma, Hepatoblastoma
- Trial name
- NCT03618381
- Testing
- second generation 4-1BBζ EGFR806-EGFRt, second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Seattle Children's Hospital
Childhood Solid Neoplasm
Tivantinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors
This phase I trial studies the side effects and best dose of tivantinib in treating younger patients with solid tumors that have returned after a period of improvement or have not responded to treatment.
- Trial name
- NCT01725191
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Tivantinib
- Where
- 20 sites in United States, Canada
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Hepatoblastoma, Previously Treated Childhood Rhabdomyosarcoma
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
This phase II trial is studying the side effects of and how well alisertib works in treating young patients with relapsed or refractory solid tumors or leukemia.
- Conditions
- Hepatoblastoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia
- Trial name
- NCT01154816
- Testing
- Alisertib, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 105 sites in United States, Canada
- Volunteers
- 118 people
- Sponsor
- Children's Oncology Group
Pediatric Cancer, Solid Tumors
Study of Eribulin in Children With Cancer to Determine Safety
This is a study for children with cancer with no curative treatment options. The investigators will be giving eribulin, a new chemotherapy agent, for the first time to children.
- Conditions
- Pediatric Cancer, Solid Tumors, Lymphoma
- Trial name
- ERIBULIN (NCT02082626)
- Testing
- Eribulin mesylate
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Oklahoma
Advanced Cancer, Metastatic Solid Tumor
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
This study will test the safety of the study drug, repotrectinib, in combination with chemotherapy (irinotecan and temozolomide) in children and young adults who have advanced or metastatic solid tumors.
- Trial name
- NCT05004116
- Testing
- Repotrectinib, Irinotecan and temozolomide
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Solid Tumor, Solid Tumor, Childhood
A Study of Romiplostim to Prevent Low Platelet Counts in Children and Young Adults Receiving Chemotherapy for Solid Tumors
The purpose of this study is to find out whether romiplostim can help prevent low platelet counts caused by N8 or EFT chemotherapy, reduce the number of platelet transfusions required during chemotherapy, and prevent treatment…
- Conditions
- Solid Tumor, Solid Tumor, Childhood, Solid Carcinoma
- Trial name
- NCT04671901
- Testing
- Romiplostim
- Where
- 7 sites in United States
- Volunteers
- 2 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Relapsed Solid Tumor, Refractory Solid Tumor
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
The study's purpose is to see if the drug, abemaciclib, is safe and effective when given with other drugs to kill cancer cells. The study is open to children and young adults with solid tumors, including neuroblastoma, that did…
- Trial name
- NCT04238819
- Testing
- Abemaciclib, Irinotecan, Temozolomide
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 47 people
- Sponsor
- Eli Lilly and Company
Childhood Cancer, Childhood Solid Tumor
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
A companion platform trial to test novel targeted agents based on the patient's tumor profile.
- Conditions
- Childhood Cancer, Childhood Solid Tumor, Childhood Brain Tumor, Recurrent Cancer
- Trial name
- NCT06208657
- Testing
- Paxalisib, Opdualag, Irinotecan (drug)
- Where
- 14 sites in Australia, Canada
- Volunteers
- 90 people
- Sponsor
- Australian & New Zealand Children's Haematology/Oncology Group
Unspecified Childhood Solid Tumor, Protocol Specific
Irinotecan and Cisplatin With or Without Amifostine in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy.
- Trial name
- NCT00004919
- Testing
- cisplatin, irinotecan hydrochloride, amifostine trihydrate
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Sickle Cell Disease, Solid Tumor
Validating Pain Scales in Children and Young Adults
Background: Assessing pain levels is important to improve treatments for different illnesses. Most pain rating scales are used to determine pain levels in adults. Pain is also a common symptom among children who have cancer.
- Conditions
- Sickle Cell Disease, Solid Tumor, Leukemia, Neurofibromatosis
- Trial name
- NCT01639950
- Where
- United States
- Volunteers
- 252 people
- Sponsor
- National Cancer Institute (NCI)
Unspecified Childhood Solid Tumor, Protocol Specific
Pharmacokinetics of Dactinomycin in Young Patients With Cancer
RATIONALE: Studying samples of blood in the laboratory from patients with cancer receiving dactinomycin may help doctors learn how dactinomycin works in the body and how patients will respond to treatment.
- Trial name
- NCT00900354
- Testing
- molecular genetic technique, mass spectrometry, pharmacological study
- Where
- 22 sites in Ireland, United Kingdom
- Volunteers
- 50 people
- Sponsor
- Children's Cancer and Leukaemia Group
Hematologic Malignancy, Hematologic Non Malignancy
Using of Virtual Reality to Relieve Procedural Pain in Pediatric Oncology.
Medical procedures can be a very frightening experience for children. It is known that children who received painful medical procedures can develop a higher sensitivity of pain during their following experiences.
- Conditions
- Hematologic Malignancy, Hematologic Non Malignancy, Solid Tumor, Childhood, Child, Only
- Trial name
- VIRTUOSO (NCT05042479)
- Testing
- Usual distraction and pain prevention techniques., Virtual reality, Choice between usual distraction or virtual reality
- Where
- France
- Volunteers
- 34 people
- Sponsor
- Nantes University Hospital